LyGenesis

LyGenesis and Imagine Pharma Announce Joint Research Collaboration to Develop Novel Cell Therapies for Patients with Type 1 Diabetes

PITTSBURGH, April 11, 2023 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology co...

iTolerance & LyGenesis: Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without Immune Suppression

iTolerance and LyGenesis announced a collaboration to evaluate the potential of iTOL-201 combined with LyGenesis' liver cell therapy (LYG-LIV-100), to enable ectopic livers to be grown without the ...

LyGenesis Adds Inborn Errors of Metabolism, Orphan Pediatric Indications ... to its Drug Development Pipeline

LyGenesis announced that it has achieved positive in vitro results of a novel combination drug-biologic product for patients with inborn errors of metabolism, adding these orphan pediatric indicati...

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

AgeX Therapeutics and LyGenesis announced today that they will proceed to negotiate an agreement for a merger of the two companies.

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease

LyGenesis, Inc. announced that the FDA has cleared its Investigational New Drug application and a study will be conducted on the safety and efficacy of its first-in-class novel cell therapy for pat...

LyGenesis Announces a New Peer-Reviewed Publication Expanding its Liver Regeneration Technology

LyGenesis, a clinical-stage biotechnology company announced today the publication of a new peer-reviewed paper published in journal Hepatology on its organ regeneration technology.